Opinion|Videos|July 18, 2024

NCCN Guidelines Revisions and ASCO 2024 Research Outlook

An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.

  1. How do you think the revised NCCN Guidelines for breast cancer will impact patient outcomes?
  2. What data, results, or insights are you looking forward to coming out of ASCO 2024?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo